Panbela Therapeutics announced it has regained compliance with applicable listing standards of The Nasdaq Stock Market for bid price and publicly held shares. Nasdaq has issued notice that Panbela has regained compliance for continued listing of its common stock. On February 13, 2024, Panbela received a letter from Nasdaq confirming that Panbela has cured the previously identified minimum bid price and the publicly held shares requirements, under Nasdaq Listing Rules 5550(a)(2) and 5550(a)(4). The Company will be presenting its plan to the Nasdaq Hearings Panel regarding equity compliance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PBLA:
- Panbela Therapeutics Issues New Shares Post-Warrant Exercise
- Panbela Therapeutics Completes Common Stock Offering
- Panbela Announces Closing of Approximately $9.0 Million Public Offering
- Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
- Panbela Therapeutics Announces Public Offering Pricing